Rhythm Pharmaceuticals Inc
NASDAQ:RYTM

Watchlist Manager
Rhythm Pharmaceuticals Inc Logo
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Watchlist
Price: 59.94 USD 1.54% Market Closed
Market Cap: 3.7B USD
Have any thoughts about
Rhythm Pharmaceuticals Inc?
Write Note

Rhythm Pharmaceuticals Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Rhythm Pharmaceuticals Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Interest Income Expense
$4.8m
CAGR 3-Years
113%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$2B
CAGR 3-Years
7%
CAGR 5-Years
-9%
CAGR 10-Years
-13%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$948m
CAGR 3-Years
26%
CAGR 5-Years
-6%
CAGR 10-Years
-10%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.4B
CAGR 3-Years
-34%
CAGR 5-Years
-29%
CAGR 10-Years
-15%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$598m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$990m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Rhythm Pharmaceuticals Inc
Glance View

Market Cap
3.7B USD
Industry
Biotechnology

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The company is headquartered in Boston, Massachusetts and currently employs 140 full-time employees. The company went IPO on 2017-10-05. The firm is focused on developing treatment for genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger (hyperphagia). The Company’s lead product candidate, IMCIVREE (setmelanotide), is a potent melanocortin-4 receptor (MC4R). IMCIVREE is developed for the treatment of rare genetic diseases of obesity. The company is focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger. The company targets the MC4R pathway to develop therapeutics for rare genetic diseases of obesity, including proopiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl syndrome (BBS), Alstrom syndrome, POMC or LEPR heterozygous deficiency obesity, Smith-Magenis syndrome, steroid receptor coactivator 1 (SRC1) deficiency obesity, MC4R deficiency obesity and SH2B adapter protein 1 (SH2B1) deficiency obesity.

RYTM Intrinsic Value
55.25 USD
Overvaluation 8%
Intrinsic Value
Price

See Also

What is Rhythm Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
4.8m USD

Based on the financial report for Sep 30, 2024, Rhythm Pharmaceuticals Inc's Interest Income Expense amounts to 4.8m USD.

What is Rhythm Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-3%

Over the last year, the Interest Income Expense growth was 633%. The average annual Interest Income Expense growth rates for Rhythm Pharmaceuticals Inc have been 113% over the past three years , -3% over the past five years .

Back to Top